OptimizeRx Survey Shows Providers Want to Engage with Patients on Drug Costs for Adherence and Improved Care
20 März 2019 - 1:31PM
OptimizeRx Corp. (NASDAQ: OPRX), a leading digital health messaging
platform for the pharmaceutical industry , released its full
results and findings from its Drug Cost Survey. The survey focused
on prescription drug costs, yielding insights into physician
perspectives on the affordability of prescription drugs and patient
adherence to prescription regimens.
Released in partnership with Jane Sarasohn-Kahn, a health
economist, advisor and industry influencer from THINK-Health LLC
and Health Populi, the full survey findings concluded that:
The cost of prescription drugs is on the mind of
physicians and patients alike.
- The vast majority of patients raise the issue of the cost of
prescription drugs with their doctors
- Most physicians (86 percent) are comfortable discussing health
care costs with patients and over 90 percent believe they have a
role to play in discussing healthcare costs with patients
- 73 percent of physicians feel patient’s responsibility for cost
is important when making a prescribing decision
Physicians believe a variety of factors that lead to
unfilled prescriptions, including:
- The high costs of prescribed medicines (70 percent)
- Intolerable or unpleasant side effects (45 percent)
- A patient’s desire not to take pills (34 percent)
- Patients already taking too many pills (31 percent)
While doctors believe they understand the reasons for
patients not filling prescriptions, too few physicians track
when patients haven’t filled that script:
- Only 5 percent of doctors “always” track an unfilled
prescription and 18 percent “usually” do so
- Taken together, that means that three-quarters of doctors
are not tracking unfilled prescriptions
“According to a recent study, lack of medication adherence costs
the U.S. health system as much as $528 billion in the context of
possible consequences, illnesses, and deaths that result from
non-optimized medication therapy,” said Sarasohn-Kahn. “Patients
are at-risk of contributing to this public health challenge when
they avoid filling prescriptions. There are strategies that can
help to risk-manage this in order to lower care costs and improve
peoples’ outcomes. We need to address this through an
ecosystem-wide, holistic lens.”
Added Miriam Paramore, president of OptimizeRx: “Shared
decision-making between patients and prescribers will be more
important than ever, and the cost-conversations and discussions
around access will be central in the patient-prescriber
relationship. We’re working tirelessly to fill this communication
gap so that providers can successfully address cost challenges to
support consumer loyalty and trust.”
The survey was the first to be executed through OptimizeMDs, a
multi-specialty physician panel created by OptimizeRx to improve
the effectiveness of digital communication between pharma/life
sciences and physicians at the point-of-care. Initial results were
released at the Healthcare Information Management Systems Society
(HIMSS) 2019 conference. OptimizeRx plans to facilitate a corollary
consumer survey to gauge their perspectives on financial
discussions, prescription affordability and medication
adherence.
The full position paper and survey results can be downloaded at
info.optimizerx.com/survey-results. For more information on
OptimizeRx, visit www.optimizerx.com.
Conducted between January 9 and 14, 2019, the survey included
responses from 642 physicians across a variety of specialties,
practice and/or hospital sizes and locations across the United
States. It was the first to be executed through OptimizeMDs, a
multi-specialty physician panel created by OptimizeRx to improve
the effectiveness of digital communication between pharma/life
sciences and physicians at the point-of-care. OptimizeMDs is one of
the brand support services available to pharmaceutical
manufacturers.
About OptimizeRxOptimizeRx® (NASDAQ: OPRX), a
digital health company, connects pharmaceutical companies
to patients and providers, offering greater affordability,
adherence and brand awareness at the point-of-care. As the nation’s
largest point-of-prescribe promotional platform for the
pharmaceutical industry, OptimizeRx provides a direct
channel for pharma companies to communicate with healthcare
providers right within their workflow and also directly to
patients.
The cloud-based solution supports patient adherence to
medications and better healthcare outcomes with real-time access to
financial assistance, prior authorization, education and critical
clinical information. OptimizeRx provides more than half
of the ambulatory patient market with access to these benefits
through leading EHR platforms like Allscripts, Amazing Charts and
Quest, and directly via its mobile communications
platform.
For more information, follow the company
on Twitter, LinkedIn or
visit www.optimizerx.com.
Important Cautions Regarding Forward Looking
Statements This press release contains forward-looking
statements within the definition of Section 27A of the Securities
Act of 1933, as amended, and such as in section 21E of the
Securities Act of 1934, as amended. These forward-looking
statements should not be used to make an investment decision. The
words 'estimate,' 'possible' and 'seeking' and similar expressions
identify forward-looking statements, which speak only as to the
date the statement was made. The company undertakes no obligation
to publicly update or revise any forward-looking statements,
whether because of new information, future events, or otherwise.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted, or quantified.
Future events and actual results could differ materially from those
set forth in, contemplated by, or underlying the forward-looking
statements. The risks and uncertainties to which forward-looking
statements are subject include, but are not limited to, the effect
of government regulation, competition and other material risks.
OptimizeRx ContactDoug Baker, CFOTel (248)
651-6568 x807dbaker@optimizerx.com
Media Relations ContactNicole Brooks, Innsena
Communications(Tel) 860-800-2344nicolebrooks@innsena.com
Investor Relations ContactRon Both, CMATel
(949) 432-7557oprx@cma.team
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jul 2023 bis Jul 2024